FindTrial
Sign In

Precise Treatment and Clinical Translation for Bladder Cancer

Precision Management and Translational Research in Bladder Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600133490
Enrollment
Unknown
Registered
2026-09-28
Start date
2026-10-10
Completion date
Unknown
Last updated
2026-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

Gold Standard:Histopathological diagnosis
Index test:A Vision Transformer (ViT) deep learning AI model based on multimodal preoperative pelvic contrast-enhanced CT/MRI imaging and multi-omics data.

Sponsors

Hunan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Minimum enrollment age >18 years; 2. No maximum age limit (represented as <100 years); 3. Suspected bladder cancer or pathologically confirmed diagnosis of bladder cancer; 4. Availability of pelvic contrast-enhanced CT/MRI imaging data.

Exclusion criteria

Exclusion criteria: 1.Patients with bladder cancer without complete preoperative pelvic contrast-enhanced CT/MRI DICOM imaging data.

Design outcomes

Primary

MeasureTime frame
AUC of the AI model for the diagnosis of bladder cancer.;—

Secondary

MeasureTime frame
AUC of combined imaging and nuclear medicine diagnosis;—

Countries

China

Contacts

Public ContactZu Xiongbing

Hunan Provincial People's Hospital

zuxbxyyy@126.com+86 731 83929085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Oct 9, 2026